This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
This product would be manufactured at Lupin's Nagpur facility in India
The ANDA was filed as 'First to File' submission on NCE-1 date.
This product will be manufactured at Lupin’s Nagpur facility in India
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
Subscribe To Our Newsletter & Stay Updated
